Asthma: Evaluation of Current and Emerging Therapies

Our Markets

Our Services

Specialties:

Asthma: Evaluation of Current and Emerging Therapies

A Survey of 107 Physicians That Treat Patients with Asthma

Deliverable: PowerPoint Presentation with key findings.

Study Description

Topic	Asthma treatments
Respondent Type	Physicians
Specialties Covered	Pulmonology, Allergy, Primary Care
Region	United States Only
Methodology	Online survey, self-administered via a Panel Intelligence website Size: 107

Objectives

To determine the potential competitive market of the novel combo agent for the treatment of asthma. This report provides insight into:

§ Current treatment for asthma by severity and by line

§ Awareness and impact of FDA alerts on the prescription of Advair

§ Future expected treatment of asthma by severity and by line

§ Awareness of Symbicort

Companies and Products Mentioned in This Report

Company	Ticker Symbol	Product(s)
GlaxoSmithKline	GSK	Advair^® (fluticasone propionate and salmeterol),
AstraZeneca	AZN	Symbicort^®(budesonide and formoterol)

Inclusion Criteria and Respondent Demographics

Inclusion Criteria

§ 107 respondents in total (74 PCPs, 17 Allergists, 16 Pulmonologists)

§ Have been in practice between 2 and 30 years

§ Spend at least 70% of their professional time in clinical practice

§ Currently treat at least 20 asthma patients per month

§ Treat both mild/moderate and severe asthma

about us